Tenofovir alafenamide fumarate
Based on 11 publication(s) in Google Scholar
Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral proagent of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 379270-38-9
- Formula: C25H33N6O9P
- Molecular Weight:592.54
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Tenofovir alafenamide fumarate
More- J Med Chem. 2024 May 9;67(9):7470-7486. [Abstract]
- Pharmaceutics. 2021 Oct 11;13(10):1656. [Abstract]
- Pharmaceuticals (Basel). 2025 Oct 16;18(10):1560. [Abstract]
- J Gastroenterol. 2020 Apr;55(4):441-452 [Abstract]
- ACS Infect Dis. 2025 Oct 30. [Abstract]
- Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02143-18. [Abstract]
- J Antimicrob Chemother. 2017 Jun 1;72(6):1731-1740. [Abstract]
- Drug Metab Dispos. 2026 Mar 2;54(5):100263. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Dec 15:1267:124803. [Abstract]
- Research Square Print. 2023 Mar 20.
- Univerzita Karlova v Praz. 2021 Jun.
-
Others
-
Cell Proliferation/Viability Assay
Biological Activity
|
HIV-1 |
HIV-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | CC50 |
>50 μM
Compound: TAF-SEE
|
Cytotoxicity against human HepG2-hNTCP cells incubated for 3 days by XTT assay
Cytotoxicity against human HepG2-hNTCP cells incubated for 3 days by XTT assay
|
[PMID: 34713696] |
| MT4 | CC50 |
35 μM
Compound: TAF-SEE
|
Cytotoxicity against in human MT4 cells after 5 days by XTT assay
Cytotoxicity against in human MT4 cells after 5 days by XTT assay
|
[PMID: 34713696] |
Tenofovir alafenamide fumarate (GS-7340 fumarate) antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC50 varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of Tenofovir alafenamide fumarate is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, Tenofovir alafenamide fumarate EC50s range from 0.1 to 12 nM, with a mean EC50 of 3.5 nM compared to a mean EC50 of 11.8 nM for Tenofovir alafenamide fumarate, which is used as an internal control. For the HIV-2 isolates, the mean EC50s are 1.8 nM for Tenofovir alafenamide fumarate and 6.4 nM for AZT[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 379270-38-9
-
Appearance Solid
-
Molecular Weight 592.54
-
Formula C25H33N6O9P
-
Color White to off-white
-
SMILES
NC1=NC=NC2=C1N=CN2C[C@@H](C)OC[P@](OC3=CC=CC=C3)(N[C@@H](C)C(OC(C)C)=O)=O.O=C(O)/C=C/C(O)=O
-
Synonyms
GS-7340 fumarate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
J Med Chem
Differential Bioactivation Profiles of Different GS-441524 Prodrugs in Cell and Mouse Models: ProTide Prodrugs with High Cell Permeability and Susceptibility to Cathepsin A Are More Efficient in Delivering Antiviral Active Metabolites to the Lung. [Abstract]2024 May 9;67(9):7470-7486. PMID: 38690769 -
Pharmaceutics
Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection. [Abstract]2021 Oct 11;13(10):1656. PMID: 34683949
Tenofovir alafenamide fumarate purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2021 Oct 11;13(10):1656. [Abstract]
The activity of rhCES1 against TAF and SBV hydrolysis was assessed. 40 ng/µL rhCES1 was incubated with 20 µM TAF or SBV at 37 °C for 5 min and 20 min, respectively.
-
Pharmaceuticals (Basel)
New Assay Systems to Characterize the Broad-Spectrum Antiherpesviral and Non-Herpesviral Activity of Cyclin-Dependent Kinase (CDK) 8 Inhibitors. [Abstract]2025 Oct 16;18(10):1560. PMID: 41155676 -
J Gastroenterol
Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay. [Abstract]2020 Apr;55(4):441-452 PMID: 31768802
Tenofovir alafenamide fumarate purchased from MedChemExpress. Usage Cited in: J Gastroenterol. 2020 Apr;55(4):441-452 [Abstract]
HepG2.2.15.7 cells were cultured for 6 days with or without a specified concentration of PDM2, and treated with or without Tenofovir alafenamide (TAF). Cell viability was determined using the MTT assay.
-
ACS Infect Dis
Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]2025 Oct 30. PMID: 41166549 -
Antimicrob Agents Chemother
CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. [Abstract]2019 Mar 27;63(4):e02143-18. PMID: 30670420 -
J Antimicrob Chemother
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. [Abstract]2017 Jun 1;72(6):1731-1740. PMID: 28369415 -
Drug Metab Dispos
A minimal physiologically based pharmacokinetic model for predicting the metabolism of tenofovir prodrugs in the liver of human with fibrosis. [Abstract]2026 Mar 2;54(5):100263. PMID: 42085925 -
J Chromatogr B Analyt Technol Biomed Life Sci
Development, validation and clinical implementation of a HPLC-MS/MS method for the simultaneous quantification of bictegravir, emtricitabine, doravirine, cabotegravir, lenacapavir, fostemsavir, tenofovir alafenamide and the corresponding metabolites temsavir and tenofovir, in human plasma. [Abstract]2025 Dec 15:1267:124803. PMID: 41072339 -
-
Solvent & Solubility
DMSO : ≥ 36 mg/mL (60.76 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 25 mg/mL (42.19 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 6.67 mg/mL (11.26 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (643 KB)
- English - EN (643 KB)
- Français - FR (643 KB)
- Deutsch - DE (643 KB)
- Norwegian - NO (643 KB)
- Español - ES (643 KB)
- Swedish - SV (643 KB)
- Italian - IT (643 KB)
- Korean - KR (643 KB)
- Portuguese - PT (643 KB)
-
Handling Instructions (2659 KB)
References
[1]. Babusis D, et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013 Feb 4;10(2):459-66. [Content Brief]
[2]. Ruane PJ, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.6876 mL | 8.4382 mL | 16.8765 mL | 42.1912 mL |
| 5 mM | 0.3375 mL | 1.6876 mL | 3.3753 mL | 8.4382 mL | |
| 10 mM | 0.1688 mL | 0.8438 mL | 1.6876 mL | 4.2191 mL | |
| 15 mM | 0.1125 mL | 0.5625 mL | 1.1251 mL | 2.8127 mL | |
| 20 mM | 0.0844 mL | 0.4219 mL | 0.8438 mL | 2.1096 mL | |
| 25 mM | 0.0675 mL | 0.3375 mL | 0.6751 mL | 1.6876 mL | |
| 30 mM | 0.0563 mL | 0.2813 mL | 0.5625 mL | 1.4064 mL | |
| 40 mM | 0.0422 mL | 0.2110 mL | 0.4219 mL | 1.0548 mL | |
| DMSO | 50 mM | 0.0338 mL | 0.1688 mL | 0.3375 mL | 0.8438 mL |
| 60 mM | 0.0281 mL | 0.1406 mL | 0.2813 mL | 0.7032 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.